Long-lasting correction of in vivo LTP and cognitive deficits of mice modelling Down syndrome with an α5-selective GABAA inverse agonist.

Date publication

octobre 2019

Journal

British journal of pharmacology

Auteurs

Membres identifiés du Cancéropôle Est :
Dr HERAULT Yann

Tous les auteurs :
Duchon A, Gruart A, Albac C, Delatour B, Zorrilla de San Martin J, Delgado-García JM, Hérault Y, Potier MC

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/31652355

Résumé

Excessive GABAergic inhibition contributes to cognitive dysfunctions in Down syndrome (DS). Selective negative allosteric modulators (NAMs) of α5-containing GABA receptors such as α5IA restore learning and memory deficits in Ts65Dn mice modelling DS. This study aimed at testing long-lasting effects of α5IA on in vivo long-term potentiation (LTP) and behavior in Ts65Dn mice.

Référence

Br. J. Pharmacol.. 2019 Oct 25;: